Document Detail


CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.
MedLine Citation:
PMID:  12883487     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previous studies suggest that hepatic cytochrome P450 2E1 (CYP2E1) activity is increased in individuals with chronic alcoholism, nonalcoholic steatohepatitis (NASH), and morbid obesity, and may contribute to liver disease. We studied 16 morbidly obese subjects with varying degrees of hepatic steatosis and 16 normal-weight controls. Obese subjects were evaluated at baseline, 6 weeks, and 1 year after gastroplasty, a procedure that leads to weight loss. Hepatic CYP2E1 activity was assessed by determination of the clearance of chlorzoxazone (CLZ), an in vivo CYP2E1-selective probe. Liver biopsy tissue was obtained during surgery for histopathology. Both the total and unbound oral CLZ clearance (Cl(u)/F) was elevated approximately threefold in morbidly obese subjects compared with controls (P <.001). The Cl(u)/F was significantly higher among subjects with steatosis involving >50% of hepatocytes, compared with those with steatosis in < or =50% of hepatocytes (P =.02). At postoperative week 6 and year 1, the median body mass index (BMI) of subjects who underwent gastroplasty decreased by 11% and 33%, total oral CLZ clearance declined by 16% (P <.01) and 46% (P <.05), and Cl(u)/F decreased by 18% (P <.05) and 35% (P =.16), respectively. Moreover, those subjects with a year 1 BMI <30 kg/m(2) exhibited a median Cl(u)/F that was 63% lower (P =.02) than the respective clearance for all other subjects. In conclusion, hepatic CYP2E1 activity is up-regulated in morbidly obese subjects. A positive association between the degree of steatosis and CYP2E1 activity preoperatively and between the extent of obesity and CYP2E1 activity postoperatively, suggests that CYP2E1 induction is related to or caused by hepatic pathology that results from morbid obesity.
Authors:
Maurice G Emery; Jeannine M Fisher; Jenny Y Chien; Evan D Kharasch; E Patchen Dellinger; Kris V Kowdley; Kenneth E Thummel
Related Documents :
8977057 - Medicating the obese patient.
15063757 - Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypoth...
12186577 - Physical activity, dietary intake, and the insulin resistance syndrome in nondiabetic a...
17320817 - Proteomic of lipid rafts in the exocrine pancreas from diet-induced obese rats.
3170777 - Slow and incomplete histological and functional recovery in adult gluten sensitive ente...
7459007 - The influence of diet-induced hypercholesterolemia on the degree of oxidation of glutat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  38     ISSN:  0270-9139     ISO Abbreviation:  Hepatology     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-07-28     Completed Date:  2003-08-29     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  428-35     Citation Subset:  IM    
Affiliation:
Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose
Chlorzoxazone / diagnostic use,  pharmacokinetics
Cytochrome P-450 CYP2E1 / metabolism*
Enzyme Activation
Fatty Liver / metabolism*,  pathology
Female
Gastric Bypass
Humans
Liver / enzymology*,  pathology
Male
Muscle Relaxants, Central / diagnostic use,  pharmacokinetics
Obesity, Morbid / metabolism*,  pathology,  surgery
Severity of Illness Index
Weight Loss / physiology*
Grant Support
ID/Acronym/Agency:
ES02728/ES/NIEHS NIH HHS; GM48349/GM/NIGMS NIH HHS; GM48712/GM/NIGMS NIH HHS; K24 DK02957/DK/NIDDK NIH HHS; M01 RR00037/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Muscle Relaxants, Central; 95-25-0/Chlorzoxazone; EC 1.14.14.1/Cytochrome P-450 CYP2E1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.
Next Document:  Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty...